Table 1.
Patient Characteristics at time of Coronary Stent Placement by Drug Metabolism Phenotype
| Characteristic | Poor/Intermediate Metabolizer (n= 514) | Nonactionable (n= 2162)a | P-valueb | ||
|---|---|---|---|---|---|
| Age, mean (SD), y | 64 | (11) | 64 | (12) | 0.57 |
| Female Sex, No. (%) | 153 | (29.8) | 651 | (30.1) | 0.88 |
| Race, No. (%) | 0.59d | ||||
| White | 449 | (87.4) | 1923 | (88.9) | |
| Black | 41 | (8.0) | 152 | (7.0) | |
| Other | 24 | (4.7) | 87 | (4.0) | |
| Weight, mean (SD), kg | 92 | (24) | 91 | (22) | 0.62 |
| Cardiac Risk Factors, No· (%) | |||||
| Smoking, ever | 68 | (13.2) | 324 | (15.0) | 0.31 |
| Cerebrovascular disease | 30 | (5.8) | 139 | (6.4) | 0.62 |
| Chronic lung disease | 48 | (9.3) | 236 | (10.9) | 0.30 |
| Congestive Heart Failure | 279 | (54.3) | 1128 | (52.2) | 0.39 |
| Diabetes Mellitus | 154 | (30.0) | 584 | (27.0) | 0.18 |
| Family History of CAD | 181 | (35.2) | 667 | (30.9) | 0.06 |
| Hypercholesterolemia | 322 | (62.6) | 1271 | (58.8) | 0.11 |
| Hypertension | 314 | (61.1) | 1215 | (56.2) | 0.04 |
| Peripheral Vascular Disease | 56 | (10.9) | 175 | (8.1) | 0.04 |
| Previous CABG | 24 | (4.7) | 148 | (6.8) | 0.07 |
| Previous PCI | 88 | (17.1) | 426 | (19.7) | 0.18 |
| Indication for coronary catheterization, No. (%)c | |||||
| Arrhythmia | 15 | (2.9) | 53 | (2.5) | 0.55 |
| Unstable angina | 133 | (25.9) | 521 | (24.1) | 0.40 |
| Chest pain | 45 | (8.8) | 165 | (7.6) | 0.40 |
| Myocardial infarction | 31 | (6.0) | 125 | (5.8) | 0.83 |
| Transplant related | 15 | (2.9) | 48 | (2.2) | 0.35 |
| Stable Angina | 120 | (23.3) | 391 | (18.1) | 0.01 |
| Other | 213 | (41.4) | 830 | (38.4) | 0.20 |
| Urgency of catheterization, No. (%)c | 0.35d | ||||
| Elective | 326 | (63.4) | 1306 | (60.4) | |
| Urgent | 90 | (17.5) | 357 | (16.5) | |
| Emergent | 4 | (0.8) | 14 | (0.6) | |
| Salvage | 0 | (0.0) | 1 | (0.0) | |
| Not Recorded | 94 | (18.3) | 484 | (22.4) | |
| Baseline Antiplatelet Therapy, No. (%)c | 0.25d | ||||
| Clopidogrel (Plavix) 75 mg | 221 | (43.0) | 962 | (44.5) | |
| Clopidogrel (Plavix) 150 mg | 1 | (0.2) | 6 | (0.3) | |
| Prasugrel (Effient) 10 mg | 19 | (3.7) | 44 | (2.0) | |
| Ticagrelor (Brillinta) 180 mg | 1 | (0.2) | 7 | (0.3) | |
| None | 272 | (52.9) | 1143 | (52.9) | |
| Coronary stent type, No· (%) | 0.8 | ||||
| Bare metal stent | 146 | (28.4) | 646 | (29.9) | |
| 1st generation DES | 24 | (4.7) | 102 | (4.7) | |
| 2nd generation DES | 344 | (66.9) | 1414 | (65.4) | |
Abbreviations: CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; DES, drug eluting stent
a
“Nonactionable” includes normal, indeterminate, and uncharacterized metabolizers who lack a loss-of-function CYP2C19 allele
b
Two-sided P values calculated with Wilcoxon or Pearson test
c
Multiple indications could be selected per coronary catheterization procedure
d
P-values are calculated across all categories